SAN DIEGO, CA, December 14, 2011 — OncoSec Medical Inc.(OTCBB:ONCS), a biotechnology company developing its advanced-stage Oncology Medical System (OMS) ElectroOncology therapies to treat skin cancer and other solid tumor cancers, has hired The Investor Relations Group (“IRG”), a fifteen-year-old, award-winning, corporate communications firm based in NewYork City, to serve as its investor relations and public relations agency.
IRG’s investor relations team will target specific portfolio managers and equity analysts in the global investment community to increasea wareness of OncoSec Medical’s therapies, which combine the Company’s proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutic. Concurrent with that effort, the public relations team will initiate an outreach campaign targeting editors, writers, and segment producers of local and national trade and consumer online, print, radio, and broadcast media outlets worldwide.
“OncoSec Medical has outlined a bold set of initiatives for 2012 and beyond, and we are confident that IRG will serve as an excellent liaison to the investment community and the media at large,” commented Punit Dhillon, President and Chief Executive Officer. “We are especially looking forward to initiating and obtaining results from our three Phase II safety and efficacy trials, which will use our OMS ElectroImmunotherapy technology to deliver DNA IL-12 to patients with metastatic melanoma, Merkel cell carcinoma, and cutaneous t-cell lymphoma. With our extensive clinical experience, and positive results from the Phase I malignant melanoma study which demonstrated best-in-class local and systemic responses, we strongly believe that our electroporation delivery technology offers a uniquely powerful and compelling new approach to treating solid tumor cancers. We look forward to working with IRG as we achieve our objectives andwill update the investment community as we move ahead.”
IRG’s corporate communications program includes new media and multimedia initiatives that involve the creation of broadcast-ready corporate videos, podcasts, and the creation of social networking, video service, and micro-blogging accounts. The Investor Relations Group was recently honored with a “Stevie Award” for Investor Relations Program of the Year and named a finalist in the BestMedia Website category from the 2009 American Business Awards.
OncoSec Medical Incorporated (OTCBB: ONCS) develops novel OMS ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted local delivery of these agents is designed to achieve selective destruction of cancerous tumors while sparing healthy normal tissue, resulting in improved functional, cosmetic and quality of life outcomes. These therapieshave achieved validating safety and efficacy data in early and late stage clinical studies of over 400 cancer patients. OncoSec’s clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy. More information is available at www.oncosec.com. Additional information may also be found at OncoSec’s Facebook , Twitter, and LinkedIn sites.
* * *
This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such “forward looking statements.” Forward looking statements are based on management’s current preliminary expectations and are subject to risks and uncertainties which may cause ourresults to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec’s filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obligation to update any forward looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.
|Who We Are||Current Clinical Trials||ImmunoPulse® IL-12|
|Join the Team||Previous Clinical Trials||Combination Approach|